Compile Data Set for Download or QSAR
Report error Found 923 Enz. Inhib. hit(s) with Target = 'Histone acetyltransferase KAT5'
TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM730972(N-{6-[(3-cyclopropyl-1 H-pyrazol-5-yl)amino]-5-met...)
Affinity DataKi:  1nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM730973(N-{6-[(3-cyclopropyl-1 H-pyrazol-5-yl)amino]-5-met...)
Affinity DataKi:  5.80nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM731036(US20250122183, Example 249)
Affinity DataKi:  8.70nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM731013(US20250122183, Example 226)
Affinity DataKi:  11.6nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM730793(US20250122183, Example 005)
Affinity DataKi:  13.6nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM730940(N-{6-[(3-cyclopropyl-1 H-pyrazol-5-yl)amino]-5-met...)
Affinity DataKi:  17.4nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM730882(US20250122183, Example 095)
Affinity DataKi:  18.1nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM730906(US20250122183, Example 119)
Affinity DataKi:  19.4nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM730990(US20250122183, Example 203)
Affinity DataKi:  21.7nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM730989(US20250122183, Example 202)
Affinity DataKi:  25.4nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM731010(US20250122183, Example 223)
Affinity DataKi:  25.4nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM731009(US20250122183, Example 222)
Affinity DataKi:  27.9nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM730933((stereospecific Procedure): N-{6-[(3-cyclopropyl-1...)
Affinity DataKi:  31.4nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM730869(US20250122183, Example 082)
Affinity DataKi:  33.8nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM731029(2,6-dimethoxy-N-(5-methoxy-6-{[3-(2-methylcyclopro...)
Affinity DataKi:  34nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM730855(US20250122183, Example 068)
Affinity DataKi:  39.3nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM730930(N-{6-[(3-cyclopropyl-1 H-pyrazol-5-yl)amino]-5-met...)
Affinity DataKi:  44.3nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM730909(US20250122183, Example 122)
Affinity DataKi:  45.3nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM730796(US20250122183, Example 008)
Affinity DataKi:  46.9nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM730851(US20250122183, Example 064)
Affinity DataKi:  48.1nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM730795(US20250122183, Example 007)
Affinity DataKi:  53.6nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM731041(US20250122183, Example 254)
Affinity DataKi:  54.5nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM730971(N-{6-[(3-cyclopropyl-1 H-pyrazol-5-yl)amino]-5-met...)
Affinity DataKi:  60.7nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM730905(US20250122183, Example 118)
Affinity DataKi:  66.1nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM731038(US20250122183, Example 251)
Affinity DataKi:  67nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM580675(US11492346, Example 15)
Affinity DataKi:  70nMAssay Description:A. Compound preparation 1. Prepare 10 mM stock solutions in 100% DMSO from solid material 2. Serial dilute 10 mM, 1 mM or 0.1 mM compound stocks 3-fo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM730935(N-{6-[(3-cyclopropyl-1 H-pyrazol-5-yl)amino]-5-met...)
Affinity DataKi:  78.1nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM730871(US20250122183, Example 084)
Affinity DataKi:  82.3nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM731046(US20250122183, Example 259)
Affinity DataKi:  85.1nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM730941(US20250122183, Example 154)
Affinity DataKi:  88.3nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM730998(US20250122183, Example 211)
Affinity DataKi:  89.4nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM730967(N-{6-[(5-cyclopropyl-1 H-pyrazol-3-yl)amino]-5-met...)
Affinity DataKi:  94.8nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM730902(US20250122183, Example 115)
Affinity DataKi:  101nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM653650(US11911372, Example 72 | US20240277683, Example 72)
Affinity DataIC50: 106nMAssay Description:o determine the inhibition of KAT enzymatic activity by test compounds, assay reactions were conducted in a volume of 8 uL in 384-well low volume ass...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM730996(N-{6-[(3-cyclopropyl-1 H-pyrazol-5-yl)amino]-5-met...)
Affinity DataKi:  106nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM730939(N-{6-[(3-cyclopropyl-1 H-pyrazol-5-yl)amino]-5-met...)
Affinity DataKi:  106nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM730908(US20250122183, Example 121)
Affinity DataKi:  106nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM653650(US11911372, Example 72 | US20240277683, Example 72)
Affinity DataIC50: 106nMAssay Description:To determine the inhibition of KAT enzymatic activity by test compounds, assay reactions were conducted in a volume of 8 μL in 384-well low volu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM580750(US11492346, Example 92)
Affinity DataKi:  110nMAssay Description:A. Compound preparation 1. Prepare 10 mM stock solutions in 100% DMSO from solid material 2. Serial dilute 10 mM, 1 mM or 0.1 mM compound stocks 3-fo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM580661(US11492346, Example 1)
Affinity DataKi:  120nMAssay Description:A. Compound preparation 1. Prepare 10 mM stock solutions in 100% DMSO from solid material 2. Serial dilute 10 mM, 1 mM or 0.1 mM compound stocks 3-fo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM730812(US20250122183, Example 025)
Affinity DataKi:  121nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM580678(US11492346, Example 18)
Affinity DataKi:  130nMAssay Description:A. Compound preparation 1. Prepare 10 mM stock solutions in 100% DMSO from solid material 2. Serial dilute 10 mM, 1 mM or 0.1 mM compound stocks 3-fo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM730834(US20250122183, Example 047)
Affinity DataKi:  131nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM730928(N-{6-[(3-cyclopropyl-1 H-pyrazol-5-yl)amino]-5-met...)
Affinity DataKi:  134nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM730784(US20250122183, Example 003)
Affinity DataKi:  138nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM653602(US11911372, Example 23 | US20240277683, Example 23)
Affinity DataIC50: 140nMAssay Description:o determine the inhibition of KAT enzymatic activity by test compounds, assay reactions were conducted in a volume of 8 uL in 384-well low volume ass...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM730975(N-{6-[(3-cyclopropyl-1 H-pyrazol-5-yl)amino]-5-met...)
Affinity DataKi:  140nMAssay Description:1. Final reaction conditions are 12.5 nM KAT5 Full length enzyme, 1 μM AcCoA, 2 μM H4 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM653602(US11911372, Example 23 | US20240277683, Example 23)
Affinity DataIC50: 140nMAssay Description:To determine the inhibition of KAT enzymatic activity by test compounds, assay reactions were conducted in a volume of 8 μL in 384-well low volu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM653593(US11911372, Example 14 | US20240277683, Example 14)
Affinity DataIC50: 142nMAssay Description:To determine the inhibition of KAT enzymatic activity by test compounds, assay reactions were conducted in a volume of 8 μL in 384-well low volu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetHistone acetyltransferase KAT5(Human)
Pfizer

US Patent
LigandPNGBDBM653593(US11911372, Example 14 | US20240277683, Example 14)
Affinity DataIC50: 142nMAssay Description:o determine the inhibition of KAT enzymatic activity by test compounds, assay reactions were conducted in a volume of 8 uL in 384-well low volume ass...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
US Patent

Displayed 1 to 50 (of 923 total ) | Next | Last >>
Jump to: